OVERVIEW

This session focuses on education and training for rapid and inhalable insulin prescribing and education for people with type 1 diabetes with the goal to effectively increase patients’ Time-In- Range and decrease post-prandial hyperglycemia and time in hyperglycemia.

The outcomes will be measured by an analysis of numerical data obtained through participant evaluation of the stated learning outcomes.

Target Audience

This activity is designed for all faculty, residents, physician asistants, diabetes educators, pharmacists, and nurses.

Learning Objectives

At the conclusion of this activity, participants should be better able to: report an increased awareness of the most current therapeutic modalities and medication regimens related to rapid and inhaled insulins for mealtime and correction boluses to effectively increase patients’ Time-In-Range and decrease post-prandial hyperglycemia and time in hyperglycemia.

METHOD OF PARTICIPATION AND HOW TO RECEIVE CME CREDIT

There are no fees for participating in and receiving credit for this activity.

• Review the activity objectives, faculty information, and CME information prior to participating in the activity.
• View the presentation
• Complete this survey so you may receive credit for viewing.

FACULTY DISCLOSURE

In accordance with the disclosure policy of The Association of Diabetes Care & Education Specialists CME Office as well as standards set forth by the Accreditation Council on Continuing Medical Education (ACCME), speakers have been asked to disclose any relevant financial relationship with the manufacturers of any commercial products and/or provider of commercial services discussed in any educational presentation and with any commercial supporters or exhibitors of this activity.

The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation but to identified openly so that the listener may form his/her own opinion. Any potential conflicts of interest have been resolved prior to this presentation.

This activity may include discussion of off-label or investigative drugs uses. Speakers are aware that it is their responsibility to disclose to the audience this information. Individual Faculty Disclosure information may be found in the conference handouts.

Faculty Disclosure/Conflict of Interest

The following speakers and planning committee members* have disclosed that they have no relevant financial relationships:

• Halis Akturk, MD
• Nicole Rioles, MA*
• Holly Hardison, BS*
• Ori Odugbesan, MD, CPHQ*
• RN, Jeniece Ilkowitz, RN, MA, CDCES*
• Todd Alonso, MD*
• Kyle Bertram, PharmD, BCACP, CDCES*

DISCLAIMER AND PRIVACY POLICY

Privacy Policy: T1D Exchange and its educational partners protect the privacy of personal and other information regarding participants and educational collaborators. T1D Exchange maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. The CME Office will keep your personal information confidential when you participate in a CME Internet-based program. CME collects only the information necessary to provide you with the services that you request.

Disclaimer: This educational program is designed to
present scientific information and opinion to Health professionals, to stimulate thought, and further investigation.

Available credit:
1.00 AMA PRA Category 1 Credit™
1.00 APA
1.00 Attendance

Course opens: 11/9/2022
Course expires: 11/8/2023
Cost: $0.00

Part of:
Program in Educational HealthCare
Provider Development
On-Demand Courses